

mc2 therapeutics

Building leadership in topicals for chronic inflammatory conditions

CONFIDENTIAL

MC2 is positioned for transformation and growth

Mature private company

Transforming from pure R&D to commercial build-out with strong pipeline

Wynzora™ launch near term

US FDA approved on July 20th 2020 – MAA submitted in EU in June 2020

Transformative technology

PAD™ Technology is a pipeline generator - enabling a new standard of topicals

Attractive market access

Best-in-class drugs that may save costs and new drugs for “no-therapy indications”

Unique branding opportunity

PAD™ Technology and biomee™ provide a unique opportunity to engage stakeholders

An aerial photograph of a tropical cyclone, showing a large, swirling storm system with a distinct eye and surrounding cloud bands. The water is a deep blue, and the clouds are white and grey. The text is overlaid on the image in a clean, white, sans-serif font.

MC2 has developed the most powerful vehicle for topicals

pad
technology™

releasing the full potential


PAD™ Technology – the making of a unique oil-in-water dispersion – a new standard



- **Chemical stability:** Protects molecules from water
- **Physical stability:** Reduced risk of droplet collapse enables a broader formulation space for stability and solubility
- **Tolerability:** Several fold less surfactants compared to conventional creams and lotions
- **Delivery - efficacy:** Fully solubilized active ingredients, optimal saturation and low amount of surfactants enable optimal delivery of actives to target tissue

PAD™ Technology is the innovative solution to important unmet needs

Releasing full potential of potent molecules



- Effect
- Tolerability
- Convenience

New patents



- Expanded formulation space
- Know-how

Payers need better topicals to save costs



Annual patient cost
Biologics >\$30,000
Topicals ~ \$2,000

Patients need better treatment experience



Greasy Vaseline-like formulations


UPGRADE!



- Non-greasy cream
- High tolerability
- Pleasant in daily routines

The innovative solution

pad
technology™



Scanning electron microscopy image of PAD™ droplet

There is an unmet need for topicals that address all of three fundamentals:



Releasing full clinical potential in real life

Rx pipeline: Mature and targeting major chronic inflammatory conditions

Program	Active Ingredient	Indication	MC2 Rights	Pre-Clinical	Phase 2	Phase 3	Filing	Approved	
Wynzora™ Cream	Calcipotriene + BDP	Psoriasis	Worldwide 2038	US				Approved	
				EU			MAA filed June 2020	H1 2021	
MC2-03	Ciclosporin	Sjögren Severe Dry Eye	Worldwide 2032	Ph3 in planning				TBD	
MC2-11	Tacrolimus	Atopic Dermatitis	Worldwide 2037					TBD	
MC2-22	Crisaborole	Atopic Dermatitis	Worldwide 2038, FTO 27'					TBD	
MC2-25	Repurposed Known Molecule	Uremic Pruritus	Worldwide 2038					TBD	
MC2-27	Repurposed Known Molecule	Lichen Sclerosus	Worldwide 2040					TBD	

Our “Stay Intact” strategy for transformation and growth is fully mapped out

Onboard attractive new opportunities

LONGER TERM ▶

Building acquisition and licensing capabilities

Onboard marketed drugs and/or clinical stage NCE's
Ideally suitable for an upgrade using PAD™ Technology

Commercialize & continue to build

ON-GOING ▶

Commercial out-build

US & EU: Build commercial infrastructure
ROW: Out-license

PAD™ Rx Pipeline

- MC2-03 Ciclosp. (dry eye) Ph3 prep.
- MC2-11 Tacrolimus (AD) Ph2 prep.
- MC2-22 Crisaborole (AD) Ph2 prep.
- MC2-25 Uremic Pruritus IND prep.
- MC2-27 Lichen Sclerosus IND prep.

Leverage existing favorable position

EXISTING ▶

Drugs

Wynzora™ Cream

US: Approved
www.wynzora.com

EU: MAA filed June 20'

pad
technology™

Pipeline generator

- Upgrade marketed Rx
- Enable NCE's
- LCM - New patents

biomee™ (non-Rx)

- MC2-02 Anti-itch
- MC2-10 Sanitizer
- MC2-18 Barrier
- MC2-21 Dry skin

Experienced leadership and strong owners

mc2 therapeutics



biomee™

Innovative skin care line
for dry and itchy skin

biomee™ skin care line – powerful and pure PAD™ creams for dry & itchy skin

Anti-itch
Urea exposed skin



- **Highly tolerable**
unique low emulsifier <1%

Dry Skin
Filaggrin deficiency



- **Uniquely designed**
Special dry and itchy skin

Barrier
Protect against irritants




- **New feel and experience**
pleasant in daily routines


















Sanitizer
Hand Sanitizer Lotion



Our business goals are synergistic and enhances brand value of PAD™ Technology



Experienced leadership team

Executive	Previous Experience	Executive	Previous Experience
 <p>Jesper J. Lange, LL.M. President & CEO</p>	  <p>Attorney - Partner - M&A</p>	 <p>Ann Kristin Led, Exec. VP Finance & Strategy</p>	 <p>Business Development Director</p>
 <p>Johan Selmer, MD Chief Medical Officer</p>	 <p>Senior Medical Scientist</p>  <p>Various managerial positions</p>	 <p>Frédéric Gomez, Msc Business Development</p>	 <p>Head of Business Development</p>  <p>Research Analyst</p>
 <p>Morten Præstegaard, PhD Chief Operating Officer</p>	 <p>Research Manager</p>  <p>Department Manager (Biolmage spin-off)</p>	 <p>Christopher Billis Chief Commercial Officer</p>	 <p>Commercial Strategy Dermatology</p>  <p>Marketing and Sales</p>

Support by experienced board of directors and strong owners

Board of Directors

Name	Experience
Mads Clausen Chairman and Owner	Led the establishment of MC2 Therapeutics and serves as Chairman of the Board
Anders D. Hove, M.D. Director	Served most recently as a managing general partner at Venrock Associates (“Venrock”), a venture capital firm, which he joined in 2004 focusing on private and public biotech investments
Mette Vagner Johannesen Director	Held executive roles in finance, strategy, HR, administration and general management
Jesper J. Lange, LL.M. Director	Co-founder of MC2 Therapeutics and joined the company from his position as partner in a major Danish law firm

Owners

Name	Commentary
Mads Clausen	Grandson of Danish industrialist and founder of Danfoss A/S
Johan Schrøder family	Former owner of Radiometer A/S



pad
technology™
powerful & pure